Bromodomain Extraterminal (BET) Family Inhibitor JQ1 Inhibits Nuclear Maturation and Cytoplasmic Organization of Oocytes.

被引：0
|
作者：
Poojary, Keerthana Karunakar [1 ]
Kumari, Sandhya [1 ]
Adiga, Satish K. [1 ]
Kalthur, Guruprasad [1 ]
机构：
[1] Kasturba Med Coll & Hosp, Udupi, India
来源：
REPRODUCTIVE SCIENCES | 2021年 / 28卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
O-051
引用
收藏
页码：68A / 68A
页数：1
相关论文
共 50 条
  • [31] The BET bromodomain inhibitor JQ1 radiosensitizes non-small cell lung cancer cells by upregulating p21
    Wang, Jian
    Wang, Ye
    Mei, Hong
    Yin, Zhongyuan
    Geng, Yuanyuan
    Zhang, Tao
    Wu, Gang
    Lin, Zhenyu
    CANCER LETTERS, 2017, 391 : 141 - 151
  • [32] Selective BET-bromodomain inhibition by JQ1 suppresses dendritic cell maturation and antigen-specific T-cell responses
    Niklas Remke
    Savita Bisht
    Sebastian Oberbeck
    Jens Nolting
    Peter Brossart
    Cancer Immunology, Immunotherapy, 2021, 70 : 107 - 121
  • [33] Cooperative effects of the tyrosine kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on several human carcinoma cell lines
    Bauer, K.
    Berger, D.
    Zielinski, C. C.
    Valent, P.
    Grunt, T. W.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 307 - 307
  • [34] GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
    Kumar, Krishan
    Raza, Sania S.
    Knab, Lawrence M.
    Chow, Christina R.
    Kwok, Benjamin
    Bentrem, David J.
    Popovic, Relja
    Ebine, Kazumi
    Licht, Jonathan D.
    Munshi, Hidayatullah G.
    SCIENTIFIC REPORTS, 2015, 5
  • [35] GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
    Krishan Kumar
    Sania S. Raza
    Lawrence M. Knab
    Christina R. Chow
    Benjamin Kwok
    David J. Bentrem
    Relja Popovic
    Kazumi Ebine
    Jonathan D. Licht
    Hidayatullah G. Munshi
    Scientific Reports, 5
  • [36] BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
    Ning Li
    Lu Yang
    Xue-Kang Qi
    Yu-Xin Lin
    Xinhua Xie
    Gui-Ping He
    Qi-Sheng Feng
    Ling-Rui Liu
    Xiaoming Xie
    Yi-Xin Zeng
    Lin Feng
    Cell Death & Disease, 9
  • [37] The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling
    Zhang, Huan-Tian
    Gui, Tao
    Sang, Yuan
    Yang, Jie
    Li, Yu-Hang
    Liang, Gui-Hong
    Li, Thomas
    He, Qing-Yu
    Zha, Zhen-Gang
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2017, 118 (08) : 2182 - 2192
  • [38] BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
    Li, Ning
    Yang, Lu
    Qi, Xue-Kang
    Lin, Yu-Xin
    Xie, Xinhua
    He, Gui-Ping
    Feng, Qi-Sheng
    Liu, Ling-Rui
    Xie, Xiaoming
    Zeng, Yi-Xin
    Feng, Lin
    CELL DEATH & DISEASE, 2018, 9
  • [39] BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression as well as proliferation of cutaneous T-cell lymphoma
    Sugaya, M.
    Kamijo, H.
    Takahshi, N.
    Oka, T.
    Miyagaki, T.
    Asano, Y.
    Sato, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S116 - S116
  • [40] Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts
    Bian, Benjamin
    Bigonnet, Martin
    Gayet, Odile
    Loncle, Celine
    Maignan, Aurelie
    Gilabert, Marine
    Moutardier, Vincent
    Garcia, Stephane
    Turrini, Olivier
    Delpero, Jean-Robert
    Giovannini, Marc
    Grandval, Philippe
    Gasmi, Mohamed
    Ouaissi, Mehdi
    Secq, Veronique
    Poizat, Flora
    Nicolle, Remy
    Blum, Yuna
    Marisa, Laetitia
    Rubis, Marion
    Raoul, Jean-Luc
    Bradner, James E.
    Qi, Jun
    Lomberk, Gwen
    Urrutia, Raul
    Saul, Andres
    Dusetti, Nelson
    Iovanna, Juan
    EMBO MOLECULAR MEDICINE, 2017, 9 (04) : 482 - 497
12345